Efinaconazole

Description

Efinaconazole · CAS 164650-44-6 · C18H22F2N4O. UNII J82SB7FXWB.

Identification

Computed Descriptors

Physical description & handling notes

• mean ± SD plasma Cmax on Day 28 of treatment: 0.67 ± 0.37 ng/mL. mean ± SD AUC was 12.15 ± 6.91 ng*h/mL.
• For the topical treatment of onychomycosis, efinaconazole is commercially available as a 10% solution. The clear colorless to pale yellow solution contains efinaconazole in an alcohol-based vehicle. The topical solution also contains anhydrous citric acid, butylated hydroxytoluene, C12-15 alkyl lactate, cyclomethicone, diiospropyl adipate, disodium edetate, and purified water.
• Topical: Solution, 10%, (Jublia) Valeant.

GHS Hazard Classification

Documented Uses

• Indicated in the treatment of fungal infection of the nail, known as onychomycosis.
• Breast Feeding; Lactation; Anti-Infective Agents; Antifungal Agents;
• Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes. /Included in US product label/
• We sought to evaluate the efficacy of efinaconazole topical solution, 10%, in patients with onychomycosis and coexisting tinea pedis. We analyzed 1,655 patients, aged 18 to 70 years, randomized (3:1) to receive efinaconazole topical solution, 10%, or vehicle from two identical multicenter, double-blind, vehicle-controlled 48-week studies evaluating safety and efficacy. The primary end point was complete cure rate (0% clinical involvement of the target toenail and negative potassium hydroxide examination and fungal
• Onychomycosis is a common fungal infection of the nail unit that results in discoloration, subungual debris, thickening, onycholysis, and often pain and impairment of mobility. Dermatophytomas are characterized by a thick fungal mass within and under the nail plate and are especially resistant to treatment. Here we report a case of a patient with a dermatophytoma who had failed oral terbinafine but was successfully treated with efinaconazole 10% topical solution.
• Adverse effects reported in at least 1% of adults treated with efinaconazole 10% topical solution and more frequently than with topical vehicle solution include application site dermatitis, ingrown toenail, application site vesicles, and application site pain.

Synonyms

EFINACONAZOLE; 164650-44-6; (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol; JUBLIA; KP-103; efinaconazol; Clenafin; KP103; Kp 103; efinaconazolum; IDP-108; J82SB7FXWB; CHEBI:82718; (2r,3r)-2-(2,4-difluorophenyl)-3-(4-methylidenepiperidin-1-yl)-1-(1h-1,2,4-triazol-1-yl)butan-2-ol; DTXSID40167787; (2R,3R)-2-(2,4-Difluorofenil)-3-(4-metilenopiperidin-1-il)-1-(1H-1,2,4-triazin-1-il)butan-2-ol

Frequently Asked Questions

What are the CAS number and molecular formula of Efinaconazole?

CAS 164650-44-6; molecular formula C18H22F2N4O; molecular weight — g/mol.

What other names is Efinaconazole known by?

EFINACONAZOLE, 164650-44-6, (2R,3R)-2-(2,4-difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, JUBLIA, KP-103, efinaconazol.

Is Efinaconazole classified as hazardous?

Hazard statements reported: H361.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.